دورية أكاديمية
أعرض في EDS

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG).

التفاصيل البيبلوغرافية
العنوان: Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG).
المؤلفون: Rücker FG; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Corbacioglu A; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Krzykalla J; Division of Biostatistics German Cancer Research Center Heidelberg Germany., Cocciardi S; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Lengerke C; Medical Clinic, Department of Hematology, Oncology, Clinical Immunology and Rheumatology University Hospital Tübingen Tübingen Germany., Germing U; Department of Hematology, Oncology and Clinical Immunology Heinrich Heine University Düsseldorf Germany., Wulf G; Department of Hematology and Medical Oncology University Medical Center Göttingen Göttingen Germany., Samra MA; Department of Internal Medicine IV University Hospital of Gießen Gießen Germany., Teichmann LL; Department of Medicine and Polyclinic III Bonn University Hospital Bonn Germany., Lübbert M; Department of Hematology, Oncology and Stem Cell Transplantation University of Freiburg Medical Center Freiburg Germany., Kühn MWM; Department of Hematology and Oncology University Medical Center Mainz Mainz Germany., Bentz M; Department of Internal Medicine III Hospital of Karlsruhe Karlsruhe Germany., Westermann J; Department of Hematology, Oncology and Tumor Immunology Charité University Medicine Berlin Germany., Bullinger L; Department of Hematology, Oncology and Tumor Immunology Charité University Medicine Berlin Germany., Gaidzik VI; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Meid A; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Aicher S; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Stegelmann F; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Weber D; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Schrade A; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Thol F; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany., Heuser M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany., Ganser A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany., Benner A; Division of Biostatistics German Cancer Research Center Heidelberg Germany., Döhner H; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Döhner K; Department of Internal Medicine III University Hospital of Ulm Ulm Germany.
مؤلفون مشاركون: German‐Austrian Acute Myeloid Leukemia Study Group (AMLSG)
المصدر: HemaSphere [Hemasphere] 2024 Jul 15; Vol. 8 (7), pp. e123. Date of Electronic Publication: 2024 Jul 15 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2024- : [Hoboken, NJ] : Wiley
Original Publication: [Philadelphia, PA] : Wolters Kluwer Health, Inc., [2017]-
مستخلص: Competing Interests: Frank G. Rücker reports honoraria from and consultancy for Jazz Pharmaceuticals, Novartis, and BMS/Celgene; travel support from Jazz Pharmaceuticals. Michael Lübbert reports an advisory role for Abbvie, Astex Pharmaceuticals, Imago BioSciences, Janssen, Otsuka, and Syros; research support from Janssen and Cheplapharm. Michael W. M. Kühn reports honoraria from and consultancy for Pfizer, Kura Oncology, Jazz Pharmaceuticals, BMS/Celgene, and Abbvie; speakers bureau of Gilead. Lars Bullinger reports honoraria from Abbvie, Amgen, Astellas, BMS/Celgene, Daiichi Sankyo, Gilead, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, Roche, and Sanofi; research support from Bayer and Jazz Pharmaceuticals. Verena I. Gaidzik reports an advisory role for Jazz Pharmaceuticals, Abbvie, and Boehringer‐Ingelheim; speakers bureau of Pfizer, Janssen, and Abbvie; and travel support from Abbvie. Frank Stegelmann reports honoraria from and consultancy for AOP Pharma, MorphoSys, BMS/Celgene, Incyte, Novartis, and Pfizer. Felicitas Thol reports an advisory role for Novartis, BMS, Abbvie, Menarini, and Rigel. Michael Heuser reports honoraria from Certara, Jazz Pharmaceuticals, Janssen, Novartis, and Sobi; paid consultancy for Abbvie, Amgen, BMS/Celgene, Glycostem, LabDelbert, Pfizer, PinotBio, and Servier; and research funding to his institution from Abbvie, Agios, Astellas, BMS/Celgene, Glycostem, Jazz Pharmaceuticals, Karyopharm, Loxo Oncology, and PinotBio. Hartmut Döhner declares being in an advisory role for Abbvie, Agios, Amgen, Astellas, AstraZeneca, Berlin Chemie, BMS/Celgene, Daiichi Sankyo, GEMoaB, Gilead, Janssen, Jazz Pharmaceuticals, Novartis, Servier, Stemline, and Syndax; research funding from Abbvie, Agios, Amgen, Astellas, BMS/Celgene, Jazz Pharmaceuticals, Kronos Bio, Novartis, and Pfizer. Konstanze Döhner reports an advisory role for Amgen, BMS/Celgene, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, Novartis, and Roche; research funding from Agios, Astex, Astellas, BMS/Celgene, and Novartis. All other authors declare no competing interest. The remaining authors declared no conflicts of interest.
References: Blood. 2022 Sep 22;140(12):1345-1377. (PMID: 35797463)
Leukemia. 2022 Jul;36(7):1703-1719. (PMID: 35732831)
J Exp Med. 2005 Jul 4;202(1):85-96. (PMID: 15983063)
N Engl J Med. 2016 Jun 9;374(23):2209-2221. (PMID: 27276561)
Leukemia. 2023 Nov;37(11):2187-2196. (PMID: 37591941)
Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):569-74. (PMID: 9012825)
Nat Genet. 2001 Mar;27(3):263-70. (PMID: 11242107)
Leukemia. 2024 Feb;38(2):281-290. (PMID: 38228680)
Blood. 2022 Jan 6;139(1):87-103. (PMID: 34320176)
Blood Adv. 2022 Jan 11;6(1):238-247. (PMID: 34448807)
Blood. 2021 Sep 30;138(13):1137-1147. (PMID: 33951732)
Cancer Cell. 2009 Nov 6;16(5):390-400. (PMID: 19878871)
Cancer Cell. 2008 Apr;13(4):299-310. (PMID: 18394553)
Nat Rev Cancer. 2004 May;4(5):394-400. (PMID: 15122210)
Blood. 2022 Sep 15;140(11):1200-1228. (PMID: 35767897)
تواريخ الأحداث: Date Created: 20240716 Latest Revision: 20240717
رمز التحديث: 20240717
مُعرف محوري في PubMed: PMC11247273
DOI: 10.1002/hem3.123
PMID: 39011127
قاعدة البيانات: MEDLINE
الوصف
تدمد:2572-9241
DOI:10.1002/hem3.123